Skip to content
Yog Pharma
7 minute read

What a Type II Drug Master File contains, how the letter of authorization lets your ANDA reference it, and what to check on FDA's lists before you rely on one.

Almost every ANDA for a small-molecule generic references a Drug Master File for its active ingredient. The DMF is how an API manufacturer gives FDA its confidential manufacturing details without handing them to every customer. The letter of authorization is the document that connects that file to your application.

What a DMF is, and what it isn’t

A Drug Master File is a submission to FDA, described in 21 CFR 314.420, containing detailed information about the facilities, processes or materials used to make a drug. For an API, that means a Type II DMF: drug substance, intermediates and the materials used to prepare them.

Two points are often misunderstood. First, FDA does not approve a DMF. It reviews the DMF only when an application that references it is under review. Second, a US DMF has no formal open part. Unlike the European Active Substance Master File, where an applicant’s part is shared with customers, the entire US DMF stays confidential between the holder and FDA. What the manufacturer shares with you directly, usually the specification, an outline of the route and impurity data, is its decision.

How the letter of authorization works

The DMF holder authorizes FDA to review the file in support of your application by sending a letter of authorization (LOA) to FDA, submitted to the DMF itself, and a copy to you. You include that copy in your ANDA. The LOA names your company, the DMF number and the subject of the file.

If the source is a manufacturer you buy through a supplier, the LOA still comes from the DMF holder, who is normally the manufacturer. A good supplier arranges it as part of qualification. It should never be something you chase after the purchase order.

The completeness assessment

Under the Generic Drug User Fee Amendments, a Type II API DMF referenced in an ANDA requires a one-time DMF fee, and FDA runs a completeness assessment on it. DMFs that pass are published on FDA’s list of Type II API DMFs available for reference in generic drug applications. If the DMF you plan to reference is not on that list, ask why before you build a filing around it.

What to check before you reference a DMF

  1. The DMF number, type and holder name, against FDA’s published DMF list.
  2. That the status is active, and that the DMF appears on the GDUFA list of DMFs available for reference.
  3. That the manufacturing site named in the DMF is the site that will make your material.
  4. When the holder last submitted an annual report. DMFs that aren’t kept current can be closed.
  5. The holder’s commitment, in writing, to notify you of changes that could affect your application.

When the DMF changes

Holders amend their DMFs when they change a process, a site or a specification. FDA reviews the amendment, but you still have to assess whether the change affects your ANDA and whether it needs a supplement. That is why change notification belongs in your quality agreement with the supplier, with a defined notice period, rather than being left to goodwill.

Where Yog Pharma fits

With every quote we state whether a US DMF is filed for the source, its number and whether it has passed the completeness assessment. During qualification we arrange the letter of authorization from the holder and pass on change notifications as soon as we receive them.

Sources

Written by Yog Pharma for buyers and quality teams. It is general information, not regulatory advice; check the current version of each source before you rely on it in a filing.